Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CME Group Inc. (CME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a publicly traded operator in the securities and commodity exchanges industry. CME Group files a range of documents with the U.S. Securities and Exchange Commission, including current reports on Form 8-K that provide updates on financial results, corporate events and governance matters.
Recent Form 8-K filings illustrate how CME Group uses SEC reports to communicate with investors. One 8-K describes the release of quarterly financial results, including the use of non-GAAP measures such as non-GAAP revenues, expenses, operating income, net income and earnings per share, together with reconciliations to the most comparable GAAP figures. Another 8-K reports a jury verdict in favor of CME Group and the Board of Trade of the City of Chicago, Inc. in a class action involving certain Class B shareholders and members. A further 8-K discloses the planned retirement of the company’s Chief Accounting Officer and outlines the transition process.
In addition to 8-Ks, CME Group’s SEC reporting framework includes annual and quarterly reports, proxy statements and other filings that address topics such as results of operations, financial condition, risk factors, corporate governance and compensation. These documents help investors understand the company’s role as a derivatives marketplace offering futures, options, cash and OTC trading across interest rates, equity indexes, foreign exchange, energy, agricultural products, metals and cryptocurrencies, as well as its operation of CME Clearing and electronic platforms like CME Globex, BrokerTec and EBS.
On Stock Titan, CME filings are supplemented with AI-powered summaries designed to explain the key points of lengthy documents, such as 10-K and 10-Q reports, in accessible language. Users can quickly identify major themes, while still having access to the full text of each filing. The page also provides visibility into event-driven filings like Form 8-K, which can include announcements about earnings releases, legal outcomes, executive changes and other material developments.
CME Group Inc. filed a Form 144 notifying of a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC, for an aggregate market value of $97,368.96. The shares were acquired as restricted stock from the issuer on 09/15/2025 and the proposed sale date is 09/16/2025 on NASDAQ. The filing shows 360,377,042 shares outstanding, and the filer states they are unaware of any undisclosed material adverse information. No sales by the filer in the past three months are reported.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME) reported two stock sale transactions on 08/26/2025. He sold 5,930 shares of CME Class A common stock at a weighted average price of $272.10 (prices ranged $271.69–$272.58) and sold 5,966 shares at a weighted average price of $270.85 (prices ranged $270.32–$271.21). The Form 4 shows the amount of Class A shares beneficially owned following the reported transactions as 23,406 shares on the first line and 17,440 shares on the second line. The filing was signed by an authorized representative for Mr. Cutinho and includes explanatory notes about aggregated sale prices.
Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.
CME Group Inc. (CME) Form 144 notice reports a proposed sale of 32,468 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $200,054.83 and approximate sale date of 08/18/2025. The shares were acquired as restricted stock from the issuer on 05/02/2024 and were fully paid on that date. The filing lists 360,377,042 shares outstanding. Certain fields such as the identity or relationship of the selling person and the filing contact details are not populated in the provided text. The filer represents they are not aware of undisclosed material adverse information and affirms the signature and certification language required by Form 144.
CME Group director Patrick W. Maloney reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Maloney now beneficially owns 4,098 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: $145,251.96
CME Group director Harold Eugene Ford Jr. reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Ford's direct beneficial ownership increased to 2,091 shares. The Form 4 filing indicates this was a standard director compensation grant, demonstrating ongoing alignment between board member and shareholder interests.
- Transaction Type: Stock Award (Code A)
- Role: Director (Non-Employee)
- Filing Type: Individual
- Ownership: Direct
CME Group director Elizabeth A. Cook reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 532 shares of Class A Common Stock at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Cook's beneficial ownership includes:
- 18,771 shares held indirectly through a trust
- 20 shares held indirectly through a joint account
The Form 4 filing was signed by Jenelle Chalmers on behalf of Elizabeth A. Cook on June 26, 2025. This transaction represents a standard director compensation grant and demonstrates continued insider investment in the company.
CME Group director Timothy S. Bitsberger reported an insider transaction on Form 4 filed June 28, 2025, disclosing activity from June 25, 2025. Key details:
- Acquired 532 shares of Class A Common Stock at $273.03 per share
- Shares were granted through the CME Group Director Stock Plan
- Following the transaction, Bitsberger directly owns 11,121 shares
This transaction represents a standard director stock grant as part of CME Group's board compensation program. The filing was signed by Jenelle Chalmers on behalf of Bitsberger on June 26, 2025. No derivative securities were involved in this transaction.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
